SIRT With Tremelimumab and Durvalumab for Resectable HCC — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Cedars-Sinai Medical Center, Los Angeles, California Beth Israel Deaconess Medical Center, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Last updated September 2025